カテゴリ： GlobalData, オランダ, 企業調査

Qiagen NV (QIA)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7131
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：153
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：オランダ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 8
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 12
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
Qiagen NV, Medical Equipment, Deal Details 18
Asset Purchase 18
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
Venture Financing 19
ArcherDX Raises USD35 Million in Series A Financing 19
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20
Protagen Raises USD12.5 Million in Venture Financing 22
Curetis Raises USD18 Million in Extended Series B Venture Financing 23
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 25
Drug Response Dx Raises Funds Through First Round Of Venture Financing 27
Xagenic Raises US$10 Million In Series A Venture Financing 28
Partnerships 29
Qiagen Enters into Licensing Agreement with Johns Hopkins University 29
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30
Qiagen Enters into Licensing Agreement with MDxHealth 31
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40
Merck and ArcherDX Enter into Co-Development Agreement 41
QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42
Qiagen Enters into Partnership with Freenome 43
QIAGEN Enters into Agreement with Natera 44
Biomillenia Enters into Agreement with Qiagen 45
Qiagen and Centogene Enter into Co-Marketing Agreement 46
ANGLE Enters into Co-Marketing Agreement with Qiagen 47
DiaSorin Enters into Agreement with QIAGEN 48
Qiagen Forms Joint Venture with Maccura Biotech 49
ArcherDX and HeliTec Enter into Partnership 50
Singulex Enters into Agreement with Qiagen 51
Sophia Genetics Enters into Agreement with Qiagen 52
Sophia Genetics Enters into Agreement with ArcherDx 53
SeraCare Life Sciences Enters into Agreement with ArcherDx 54
Qiagen Enters into Agreement with Genohm 55
ArcherDx Enters into Partnership with PierianDx 56
ArcherDX Enters into Co-Development Agreement with Illumina 57
CareDx to Partner with Qiagen 58
Qiagen Enters into Partnership with Therawis Diagnostics 59
CosmosID Enters into Agreement with Qiagen 60
NanoString Technologies Enters into Co-Development Agreement with HalioDx 61
Qiagen Enters into Agreement with 10X Genomics 62
Qiagen Enters into Co-Development Agreement with Array BioPharma 63
ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64
Qiagen Forms Joint Venture with Biotype Diagnostics 65
Qiagen Enters into Agreement with Hitachi High-Technologies 66
Qiagen Enters into Agreement with GATC Biotech 67
Tokai Pharma Expands Agreement with Qiagen 68
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70
Qiagen Enters into Co-Development Agreement with Novartis 71
Qiagen Enters into Co-Development Agreement with Astellas Pharma 72
AstraZeneca Enters into Co-Development Agreement with Qiagen 73
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86
Qiagen Enters Into Co-Development Agreement With Eli Lilly 87
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96
Inserm Transfert Enters into Licensing Agreement with HalioDx 97
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98
Transgenomic Expands Licensing Agreement with Exiqon 99
Equity Offering 100
Exiqon Completes Private Placement Of Shares For US$2.6 Million 100
Debt Offering 101
Qiagen Raises USD400 Million in Private Placement of Notes 101
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 103
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 104
Exiqon Completes Private Placement Of Bonds For US$3 Million 105
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108
Asset Transactions 109
Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110
Acquisition 111
QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111
Qiagen Acquires STAT-Dx 112
Qiagen Acquires OmicSoft 113
Qiagen Acquires Exiqon for up to USD102.4 Million 114
Qiagen Acquires MO BIO Labs 116
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117
Qiagen Acquires CLC bio 118
Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For US$50 Million 119
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120
Qiagen NV – Key Competitors 121
Qiagen NV – Key Employees 122
Qiagen NV – Locations And Subsidiaries 123
Head Office 123
Other Locations & Subsidiaries 123
Joint Venture 126
Recent Developments 127
Financial Announcements 127
Jul 31, 2018: QIAGEN Reports Results for Second Quarter and First Half of 2018 127
May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 130
Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 132
Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 137
May 02, 2017: QIAGEN reports results for first quarter 2017 140
Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 142
Government and Public Interest 145
Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 145
Product News 146
Nov 15, 2017: QIAGEN advances precision medicine by automating guidelines on cancer variants in industry-leading QIAGEN Clinical Insight software 146
Apr 03, 2017: QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 147
Other Significant Developments 148
Sep 27, 2018: HTG Molecular announces extension to precision diagnostic partnership PDP program three for companion diagnostic submission 148
Aug 01, 2018: QIAGEN creates collaboration with Japan’s largest clinical laboratory testing company, SRL, to accelerate launch of companion diagnostics 149
Feb 07, 2018: QIAGEN and Sentieon Partner to Advance Precision Medicine With Highly Efficient Variant-Calling Software 150
Jan 08, 2018: QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements 151
Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 152
Appendix 153
Methodology 153
About GlobalData 153
Contact Us 153
Disclaimer 153

List of Tables
Qiagen NV, Medical Equipment, Key Facts, 2017 2
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Deals By Market, 2012 to YTD 2018 12
Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
ArcherDX Raises USD35 Million in Series A Financing 19
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20
Protagen Raises USD12.5 Million in Venture Financing 22
Curetis Raises USD18 Million in Extended Series B Venture Financing 23
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 25
Drug Response Dx Raises Funds Through First Round Of Venture Financing 27
Xagenic Raises US$10 Million In Series A Venture Financing 28
Qiagen Enters into Licensing Agreement with Johns Hopkins University 29
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30
Qiagen Enters into Licensing Agreement with MDxHealth 31
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 35
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 36
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 38
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40
Merck and ArcherDX Enter into Co-Development Agreement 41
QIAGEN and NeuMoDx Molecular Enter into Partnership Agreement 42
Qiagen Enters into Partnership with Freenome 43
QIAGEN Enters into Agreement with Natera 44
Biomillenia Enters into Agreement with Qiagen 45
Qiagen and Centogene Enter into Co-Marketing Agreement 46
ANGLE Enters into Co-Marketing Agreement with Qiagen 47
DiaSorin Enters into Agreement with QIAGEN 48
Qiagen Forms Joint Venture with Maccura Biotech 49
ArcherDX and HeliTec Enter into Partnership 50
Singulex Enters into Agreement with Qiagen 51
Sophia Genetics Enters into Agreement with Qiagen 52
Sophia Genetics Enters into Agreement with ArcherDx 53
SeraCare Life Sciences Enters into Agreement with ArcherDx 54
Qiagen Enters into Agreement with Genohm 55
ArcherDx Enters into Partnership with PierianDx 56
ArcherDX Enters into Co-Development Agreement with Illumina 57
CareDx to Partner with Qiagen 58
Qiagen Enters into Partnership with Therawis Diagnostics 59
CosmosID Enters into Agreement with Qiagen 60
NanoString Technologies Enters into Co-Development Agreement with HalioDx 61
Qiagen Enters into Agreement with 10X Genomics 62
Qiagen Enters into Co-Development Agreement with Array BioPharma 63
ArcherDX Enters into Co-Marketing Agreement with GenomOncology 64
Qiagen Forms Joint Venture with Biotype Diagnostics 65
Qiagen Enters into Agreement with Hitachi High-Technologies 66
Qiagen Enters into Agreement with GATC Biotech 67
Tokai Pharma Expands Agreement with Qiagen 68
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 69
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 70
Qiagen Enters into Co-Development Agreement with Novartis 71
Qiagen Enters into Co-Development Agreement with Astellas Pharma 72
AstraZeneca Enters into Co-Development Agreement with Qiagen 73
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 74
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 75
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 76
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 77
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 78
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 79
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 81
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 82
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 84
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 85
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 86
Qiagen Enters Into Co-Development Agreement With Eli Lilly 87
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 88
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 89
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 90
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 91
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 92
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 93
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 94
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 95
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 96
Inserm Transfert Enters into Licensing Agreement with HalioDx 97
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 98
Transgenomic Expands Licensing Agreement with Exiqon 99
Exiqon Completes Private Placement Of Shares For US$2.6 Million 100
Qiagen Raises USD400 Million in Private Placement of Notes 101
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 102
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 103
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 104
Exiqon Completes Private Placement Of Bonds For US$3 Million 105
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 106
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 107
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 108
Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 109
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 110
QIAGEN to Acquire Remaining 80.1% Stake in NeuMoDx Molecular for USD234 Million 111
Qiagen Acquires STAT-Dx 112
Qiagen Acquires OmicSoft 113
Qiagen Acquires Exiqon for up to USD102.4 Million 114
Qiagen Acquires MO BIO Labs 116
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 117
Qiagen Acquires CLC bio 118
Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For US$50 Million 119
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 120
Qiagen NV, Key Competitors 121
Qiagen NV, Key Employees 122
Qiagen NV, Subsidiaries 123
Qiagen NV, Joint Venture 126

List of Figures
Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 10
Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Qiagen NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 12

★海外企業調査レポート[Qiagen NV (QIA)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Eriks NV：企業の戦略・SWOT・財務情報
    Eriks NV - Strategy, SWOT and Corporate Finance Report Summary Eriks NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Antero Resources Corporation (AR)-石油・ガス分野：企業M&A・提携分析
    Summary Antero Resources Corporation (Antero), formerly Antero Resources Appalachian Corporation, is an independent oil and natural gas company that carries out exploration, development, production and acquisition of natural gas, natural gas liquids (NGLs) and oil properties in the Appalachia Basin. …
  • Vector Group Ltd (VGR)：企業の財務・戦略的SWOT分析
    Vector Group Ltd (VGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Korea Gas Corp (036460)：企業の財務・戦略的SWOT分析
    Korea Gas Corp (036460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Gastar Exploration Inc (GST)：石油・ガス：M&Aディール及び事業提携情報
    Summary Gastar Exploration Inc (Gastar), formerly Gastar Exploration Ltd, is an energy company that offers exploration and development programs. The company explores, develops and produces natural gas, oil, and natural gas liquids. Its business activities include acquisition, identification, and exp …
  • Nanophase Technologies Corp (NANX)：企業の財務・戦略的SWOT分析
    Nanophase Technologies Corp (NANX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Bio-Rad Laboratories Inc (BIO)-医療機器分野：企業M&A・提携分析
    Summary Bio-Rad Laboratories Inc (Bio-Rad) develops and manufactures specialty chemicals for use in biochemical, pharmaceutical and other life science research applications. The company offers a comprehensive range of reagents, apparatus, laboratory instruments, test systems, informatics systems, te …
  • Meritz Fire & Marine Insurance Co., Ltd.：企業の戦略・SWOT・財務分析
    Meritz Fire & Marine Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meritz Fire & Marine Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Sleep Number Corp (SNBR)：企業の財務・戦略的SWOT分析
    Sleep Number Corp (SNBR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EndoStim Inc-医療機器分野：企業M&A・提携分析
    Summary EndoStim Inc (EndoStim) is a medical device company that offers therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through el …
  • Hokka Hokka：企業の戦略・SWOT・財務分析
    Hokka Hokka - Strategy, SWOT and Corporate Finance Report Summary Hokka Hokka - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • SINTEF：企業の戦略的SWOT分析
    SINTEF - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Sembcorp Industries Ltd：企業の戦略・SWOT・財務情報
    Sembcorp Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Sembcorp Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Transport for London：企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Experian plc：企業の戦略・SWOT・財務分析
    Experian plc - Strategy, SWOT and Corporate Finance Report Summary Experian plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Samsung Electronics Co Ltd (005930)：電力：M&Aディール及び事業提携情報
    Summary Samsung Electronics Co Ltd (Samsung) is a manufacturer of consumer electronics, information technology and mobile communications, and device solutions. The company’s product portfolio includes television (TV), washing machine, refrigerator, air conditioner, medical devices, monitor, printer, …
  • NRG Energy Inc (NRG)-エネルギー分野：企業M&A・提携分析
    Summary NRG Energy, Inc. (NRG) is an integrated energy company that produces, sells and delivers energy, and energy products and services. The company generates power using diverse sources such as coal, natural gas, nuclear, oil, wind and solar. It trades wholesale energy, capacity, fuel and related …
  • Edison International：企業の戦略・SWOT・財務情報
    Edison International - Strategy, SWOT and Corporate Finance Report Summary Edison International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • China National Petroleum Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary China National Petroleum Corp (CNPC) is an integrated energy company. Its businesses cover oil and gas exploration and development, refining and chemicals, marketing and trading, pipeline transmission and stockpiling, technical services, engineering construction, equipment manufacturing, fin …
  • Vygon SA：医療機器：M&Aディール及び事業提携情報
    Summary Vygon SA (Vygon) is a medical specialty company that designs, manufactures and markets single use medical and surgical products. The company offers products in various specialties such as paediatrics, neonatology, support for post-operative pain relief, anesthesia, emergency and intensive ca …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆